mifepristone has been researched along with sorafenib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cheng, Y; Dong, H; Jia, L; Li, B; Liu, J; Liu, W; Nie, H; Wang, J; Zheng, N | 1 |
1 review(s) available for mifepristone and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for mifepristone and sorafenib
| Article | Year |
|---|---|
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemical Phenomena; Drug Compounding; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mifepristone; Nanoparticles; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Xenograft Model Antitumor Assays | 2019 |